vaccine, japanese encephalitis


Sanofi Pasteur


Zuellig Pharma
Concise Prescribing Info
Live-attenuated recombinant Japanese encephalitis virus (propagated in Vero cells)
Prophylaxis of Japanese encephalitis in persons ≥9 mth.
Dosage/Direction for Use
SC Primary immunization Person ≥9 mth 0.5 mL. Adolescent & childn up to 18 yr 0.5 mL booster dose given 1-2 yr after the 1st vaccination. Childn previously given inactivated Japanese encephalitis vaccine for primary vaccination 0.5 mL as booster dose.
History of severe allergic reaction. Postpone vaccination in case of febrile or acute disease. Congenital or acquired immune deficiency impairing cellular immunity including immunosuppressive therapies eg, chemotherapy & high doses of systemic corticosteroids given for ≥14 days. Symptomatic or asymptomatic HIV-infected patient w/ evidence of impaired immune function. Pregnancy & lactation.
Special Precautions
Do not administer intravascularly. Patients using high doses of systemic corticosteroids for ≥14 days should wait for ≥1 mth before vaccination. Vaccination must not be performed w/in 6 wk, preferably not w/in 3 mth of inj of Ig or blood products containing Ig eg, blood or plasma.
Adverse Reactions
Malaise, inj site pain/tenderness; headache; myalgia. Inj site swelling. Adult: Fatigue. Feeling hot, chills, erythema, pruritus, inj site swelling or bruising; dizziness; arthralgia; diarrhea, nausea, abdominal pain, vomiting; pharyngolaryngeal pain, dyspnea, rhinorrhea, cough, wheezing, nasal congestion; rash. Childn: Pyrexia, irritability, erythema; somnolence; vomiting; loss of appetite; crying.
Drug Interactions
Ig or blood products containing Ig eg, blood or plasma.
ATC Classification
J07BA02 - encephalitis, Japanese, inactivated, whole virus ; Belongs to the class of encephalitis viral vaccines.
Imojev inj
(1 vial of diluent, 1 syringe, 2 needles) 0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in